Review on therapeutic approach of anti-acne treatment by Azadirachta indica and Ocimum gratissimum
TMV’s Lokmanya Tilak Institute of Pharmacy, Navi-Mumbai, Maharashtra, India.
Review Article
World Journal of Advanced Research and Reviews, 2024, 22(02), 165–174
Publication history:
Received on 15 March 2024; revised on 25 April 2024; accepted on 27 April 2024
Abstract:
Millions of people worldwide suffer with acne vulgaris, a common skin ailment marked by the development of comedones, papules, pustules, and in more severe cases, nodules and cysts. There has been a boom in research into alternative remedies, especially herbal pharmaceuticals, due to growing resistance to traditional therapy and side effects associated with long-term use. Two well-known herbs with strong anti-acne effects are Ocimum gratissimum (scent leaf/ African basil) and Azadirachta indica (neem). The purpose of this review is to assess Azadirachta indica and Ocimum gratissimum's medicinal potential for acne vulgaris. We examine the phytochemistry of these herbs, emphasizing their potent components, which include thymol, eugenol, azadirachtin, nimbidin, and nimbin. These compounds have antibacterial, anti-inflammatory, and antioxidant qualities that make them useful in the treatment of acne. Finally, clinical studies examining the safety and effectiveness of topical formulations derived from Azadirachta indica and Ocimum gratissimum are reviewed, emphasizing their potential as monotherapies or adjuncts to conventional treatments. In summary, Azadirachta indica and Ocimum gratissimum represent promising candidates for the development of novel, effective, and safe herbal therapies for acne vulgaris, offering a natural alternative for people seeking sustainable and holistic approaches to skincare.
Keywords:
Azadirachta indica (Neem); Ocimum gratissimum (African Basil); Acne Therapy; Anti-Inflammatory; Antiseptic; Antioxidants
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0